ReviewFrontiers in physiology2026
Alterations in lipid metabolism and blood profile in gynecological cancers - potential strategies in diagnosis and treatment.
Review in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- FABP4 characterizes metabolic-immune interactions and serves as a prognostic biomarker across gynecologic malignancies: a multi-omics integrative analysis.Translational oncology · 2026Article
- Decoding the 2023 FIGO Staging System in Endometrial Cancer: A Practical, Visually Guided Framework for Molecular Risk-Adapted Care Incorporating the 2025 Risk Group Update.Current oncology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gynecological cancers (GCs), especially endometrial, cervical and ovarian cancers, represent a major health burden due to their increasing incidence and poor treatment outcomes, particularly in advanced stages. Numerous papers suggest that reprogramming of lipid metabolism plays an important role in the development and progression of GCs. In this review, we discuss the alterations in lipid metabolism, focusing on a) serum/plasma lipid profiles and changes in membrane lipid composition in GCs patients, b) dysregulation of fatty acid uptake and β-oxidation by GCs cells, and c) upregulation of lipogenic enzymes in cancer tissue of GCs patients and GCs cells lines. It appears that lipid alterations in the development and progression of GCs are very complex and cancer type specific. This is due to the complexity of a) the structure and properties of lipids, b) the variability between different human cancer types, and c) the need for a comprehensive set of clinical data. Moreover, the review highlights alterations of lipid metabolism as potential diagnostic and therapeutic strategies in the treatment of GC patients. Further studies are still needed to draw clear conclusions about the relationship between abnormalities in lipid metabolism and development of GCs and to bridge basic research and practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.